Discovery of fused 5,6-bicyclic heterocycles as γ-secretase modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 2, 2011, Pages 664-669

  Qin, Jun ^a   Dhondi, Pawan ^a   Huang, Xianhai ^a   Mandal, Mihirbaran ^a   Zhao, Zhiqiang ^a   Pissarnitski, Dmitri ^a   Zhou, Wei ^a   Aslanian, Robert ^a   Zhu, Zhaoning ^a   Greenlee, William ^a   Clader, John ^a   Zhang, Lili ^a   Cohen Williams, Mary ^a   Jones, Nicholas ^a   Hyde, Lynn ^a   Palani, Anandan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Secretase modulator; Alzheimer's disease; Amyloid peptide; Notch receptor

Indexed keywords

5,6 BICYCLIC HETEROCYCLE DERIVATIVE; GAMMA SECRETASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78651251055     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.012     Document Type: Article

References (31)

1. R.S. Shah, H. Lee, X. Zhu, G. Perry, M.A. Smith, and R.J. Castellani Biomed. Pharmacother. 62 2008 199
2. M. Williams Curr. Opin. Investig. Drugs 10 2009 23
3. K.L. Lanctôt, R.D. Rajaram, and N. Herrmann Ther. Adv. Neurol. Disorders 2 2009 163
4. J.A. Hardy, and G.A. Higgins Science 256 1992 184
5. J.A. Hardy, and D.J. Selkoe Science 297 2002 353
6. H. Josien Curr. Opin. Drug Discov. Devel. 5 2002 513
7. T. Harrison, I. Churcher, and D. Beher Curr. Opin. Drug Discov. Devel. 7 2004 709
8. L.A. Hyde, N.A. Mchugh, J. Chen, Q. Zhang, D. Manfra, A.A. Nomeir, H. Josien, T. Bara, J.W. Clader, L. Zhang, and E.M. Parker J. Pharmacol. Exp. Ther. 319 2006 1133
9. L.A. Hyde, Q. Zhang, N.A. Mchugh, J. Chen, R.A. Del Vecchio, G.T. Wong, D. Pissarnitski, J.W. Clader, G.A. Higgins, L. Zhang, and E.M. Parker Abstr. Soc. Neurosci. 2006 36 Abs 172.4
10. D. Pissarnitski Curr. Opin. Drug Discov. Devel. 10 2007 392
11. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo, and T.E. Golde J. Clin. Invest. 112 2003 440
12. S. Leuchtenberger, M.P. Kummer, T. Kukar, E. Czirr, N. Teusch, S.A. Sagi, R. Berdeaux, C.U. Pietrzik, T.B. Ladd, T.E. Golde, E.H. Koo, and S. Weggen J. Neurochem. 96 2006 355
13. S. Weggen, J.L. Eriksen, S.A. Sagi, C.U. Pietrizik, V. Ozols, A. Fauq, T.E. Golde, and E.H. Koo J. Biol. Chem. 278 2003 31831
14. T.L. Kukar, T.B. Ladd, M.A. Bann, P.C. Fraering, R. Narlawar, G.M. Maharvi, B. Healy, R. Chapman, A.T. Welzel, R.W. Price, B. Moore, V. Rangachari, B. Cusack, J. Eriksen, K. Jansen-West, C. Verbeeck, D. Yager, C. Eckman, W. Ye, S. Sagi, B.A. Cottrell, J. Torpey, T.L. Rosenberry, A. Fauq, M.S. Wolfe, B. Schmidt, D.M. Walsh, E.H. Koo, and T.E. Golde Nature 453 2008 925
15. T. Tomita Naunyn-Schmiedeberg's Arch. Pharmacol. 377 2008 295
16. M.S. Wolfe Neurotherapeutics 5 2008 391
17. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, and E.H. Koo Nature 414 2001 212
18. S. Weggen, J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, V. Ozols, A. Fauq, T.E. Golde, and E.H. Koo J. Biol. Chem. 278 2003 31831
19. L. Gasparini, L. Rusconi, H. Xu, P. Del Soldato, and E. Ongini J. Neurochem. 88 2004 337
20. S. Weggen, J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, T.E. Golde, and E.H. Koo J. Biol. Chem. 278 2003 30748
21. J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani, P. Wilson, and F. Kogan Neurology 43 1993 1609
22. J.J. Hoozemans, and M.K. O'Banion Curr. Drug Targets CNS Neurol. Disord. 4 2005 307
23. Kimura, T.; Kawano, K.; Doi, E.; Kitazawa, N.; Shin, K.; Miyagawa, T.; Kaneko, T.; Ito, K.; Takaishi, M.; Sasaki, T.; Hagiwara, H. PCT Int. Appl. WO2005115990, 2005.
24. Watanabe, H.; Bernier, F.; Miyagawa, T. PCT Int. Appl. WO2006112552, 2006.
25. Kushida, I.; Doi, E.; Ito, K. PCT Int. Appl. WO2006046575, 2006.
26. 40 was measured using the antibody pair of TAG-G2-10 and biotin-4G8; total Aβ was measured using TAG-W02 and biotin-4G8.
27. 42 were measured using AlphaLISA amyloid assay kits.
28. W.A. Korfmacher, K.A. Cox, K.J. Ng, J. Veals, Y. Hsieh, S. Wainhaus, L. Broske, D. Prelusky, A. Nomeir, and R.E. White Rapid Commun. Mass Spectrom. 15 2001 335
29. Absolute configuration was assigned based on chiral HPLC retention time when correlated to closely related series of enantiomers of known absolute configuration. HPLC condition: chiral OD column, hexane/i-PrOH = 4:1.
30. The exact isomeric structures of pyrazoles were not determined.
31. 2NH = 100:25:0.1.